Effect of zinc sulphate on peptic and jejunal ulcer

A clinical trial to compare the effect of high dose zinc sulphate and placebo on ulcer size of patients with peptic and jejunal ulcer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014062212789N4

Enrollment

Registered

2014-10-06

Start date

2014-07-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic ulcer. Peptic ulcer, site unspecified

Interventions

Intervention 1: In addition to triple therapy, Zinc sulfate 220 mg capsules (Alhavi pharmaceutical company) will be given to people who are in the intervention group daily. Intervention 2: The control

Treatment - Drugs

In addition to triple therapy, Zinc sulfate 220 mg capsules (Alhavi pharmaceutical company) will be given to people who are in the intervention group daily.

The control group received placebo capsules in addition to triple therapy.

Eligibility

Sex/Gender

All

Age

16 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: presence of peptic ulcer during endoscopy Exclusion criteria: presence of clear symptoms indicating malignancy in observation, presence of malignancy in pathology, patient reluctance to endoscopy, unwillingness to continuing to use the drug, drug discontinuation more than two days, diseases that impair absorption ( cirrhosis, celiac disease).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ulcer size. Timepoint: 6 weeks after initial endoscopy. Method of measurement: The ulcer would be determined by sub-specialist of gastroenterology via endoscopy.	—

Secondary

Measure	Time frame
Complications. Timepoint: During the study and 8 weeks after the initial endoscopy. Method of measurement: Observation and examination by Subspecialist of Gastroenterology.;Ulcer place. Timepoint: During the initial endoscopy. Method of measurement: Based on the location of ulcer was determined by gastroenterologist via endoscopy: stomach, antrum, fundus, cardia and duodenum.;Diarrhea and vomiting. Timepoint: During the study. Method of measurement: Observation and examination by specialist.;Dizziness. Timepoint: During the study. Method of measurement: Observation and examination by specialist.	—

Measure

Time frame

Complications. Timepoint: During the study and 8 weeks after the initial endoscopy. Method of measurement: Observation and examination by Subspecialist of Gastroenterology.;Ulcer place. Timepoint: During the initial endoscopy. Method of measurement: Based on the location of ulcer was determined by gastroenterologist via endoscopy: stomach, antrum, fundus, cardia and duodenum.;Diarrhea and vomiting. Timepoint: During the study. Method of measurement: Observation and examination by specialist.;Dizziness. Timepoint: During the study. Method of measurement: Observation and examination by specialist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Nayebi

Kurdistan University of Medical Sciences

mortazanayebi55@yahoo.com+98 87 3366 4654

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026